Close Menu

NEW YORK (GenomeWeb) – Roche Diagnostic Canada said on Tuesday that Health Canada has approved the Cobas EGFR Mutation Test v2 for marketing in that country. 

The oncology assay is the first from Roche using either plasma or tumor tissue samples and identifies 42 mutations in the epidermal growth factor receptor gene, which the firm said is the most of any in vitro diagnostic on the market. It added that the assay can also be used to help select appropriate patients with non-small cell lung cancer for therapy with an EGFR tyrosine kinase inhibitor. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.